Results 151 to 160 of about 104,817 (211)

CCL8-dependent recruitment of natural killer cells enhances the antitumor activity of neoadjuvant chemotherapy in gastric cancer. [PDF]

Cancer Immunol Immunother
Wang Y, Gao P, Peng X, Wang Z, Wu M, Hao Z, Chen L, Qian Y, Wang B, Feng D, Zhang Y, Li J, Guo M, Ding J, Zhan X.   +14 more
europepmc   +1 more source

A Disproportionality Analysis of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Agents Using the FDA Adverse Event Reporting System Database

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Objective Immune checkpoint inhibitors (ICIs) combined with platinum‐based compounds are commonly used in the treatment of certain malignant tumors. This study aims to analyze adverse events (AEs) associated with the combination therapy of ICIs and platinum‐based compounds by using the FAERS database.
Boyi Liu, Wenchao Zhang, Ruizhe Huang, Dinwen Liu, Jiaxing Liu, Ao Han, Yike Li, Danna Chen   +7 more
wiley   +1 more source

Lineage-Specific Disruption of Hematopoiesis by Oxaliplatin: Mechanisms of Erythropoietin Resistance and Immune Suppression. [PDF]

J Hematol Oncol Res
Sudlow LC, Du J, Shahverdi K, Zhou H, Berezin MY.   +4 more
europepmc   +1 more source

Locally Advanced Synchronous Hemorrhagic Gastric Cancer—From the First Symptom to Therapy—Case Report

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT Gastric cancer is one of the most common malignancies worldwide, and its incidence shows global variability, with the highest rates reported in Eastern Asia, Eastern Europe, and South America due to the aging population and growth of high‐risk groups.
Szabolcs Attila Gabor, Botond Istvan Kiss, Renata Moriczi, Evelyn Siklodi, Daniela Tatiana Sala, Radu Mircea Neagoe   +5 more
wiley   +1 more source

Oxaliplatin-induced cardiotoxicity in mice is connected to the changes in energy metabolism in the heart tissue. [PDF]

Cardiooncology
Du J, Sudlow LC, Shahverdi K, Zhou H, Michie MS, Schindler TH, Mitchell JD, Mollah S, Berezin MY.   +8 more
europepmc   +1 more source

Sustained Belinostat‐Induced Metabolic Response and Tolerability in Heavily Pretreated Relapsed/Refractory Angioimmunoblastic T‐Cell Lymphoma: A Case Report

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT Angioimmunoblastic T‐cell lymphoma (AITL), a rare and aggressive subtype of peripheral T‐cell lymphoma (PTCL), often demonstrates resistance to standard therapies. The optimal therapeutic approach for relapsed/refractory (R/R) AITL remains therefore uncertain and challenging, with an unmet need for effective treatment options.
Vassiliki Labropoulou, Evgenia Verigou, Eleni P. Kourea, Maria Liga, Dimitrios Tsokanas, Krisela‐Christina Valera, Alexandros Spyridonidis   +6 more
wiley   +1 more source

Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment [PDF]

, 2017
A Rai, AG Tolcher, AX Zhu, Caio Max S Rocha-Lima, David Portnoy, DP Brooks, E Gabriela Chiorean, E Suzuki, J Albores-Saavedra, J Nelson, J Valle, JE Rogers, JF Guion-Dussere, Jitendra Gandhi, L Goyal, M Yanagisawa, Manik Amin, NV Rajeshkumar, NV Rajeshkumar, P Papakostas, R Pazdur, Richard Kim, RK Jain, RL Siegel, S He, SC Lee, SY Oh, T Sasaki, T Walter, Tao Song, William P Harris   +30 more
core   +3 more sources

DRG Explant Model for Understanding Mechanism of Oxaliplatin-Induced Peripheral Neuropathy and Identifying Potential Therapeutic Targets. [PDF]

Antioxidants (Basel)
Du J, Sudlow LC, Luzhansky ID, Berezin MY.   +3 more
europepmc   +1 more source

Loncastuximab Tesirine in a Frail, Heavily Pretreated Patient With Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Case Report

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT Loncastuximab tesirine may offer a feasible, well‐tolerated option for frail, heavily pretreated patients with relapsed/refractory DLBCL and poor performance status when intensive therapies are unsuitable, achieving durable remission with manageable fluid retention through careful monitoring, spironolactone‐based treatment, and dose ...
Reyad Dada, Refaei Belal Ibrahim
wiley   +1 more source

Targeting the NSUN2-DHODH axis reverses ferroptosis resistance and oxaliplatin resistance in colorectal cancer. [PDF]

Front Pharmacol
Zhang J, Shen J, Zeng T, Gao C, Sheng B, Li J, Zeng W, Shen J, Shen C, Wang J, Wang J.   +10 more
europepmc   +1 more source